title: Treatment of pustular psoriasis with infliximab.
abstract: Pustular psoriasis is a severe form of psoriasis with a generalized pustular eruption. Since TNF-alpha plays an important role in pustular psoriasis, we treated two patients who had not responded to established therapy regimens with the TNF-alpha antagonist infliximab. Both patients showed significant improvements of their skin eruption and their general condition within three days after treatment and without any side effects. We suggest that infliximab is a therapeutic option for severe therapy-resistant pustular psoriasis because a single well-tolerated dose significantly ameliorates the patient's condition.
authors: Clinic and Polyclinic for Skin Diseases, Münster University Hospital, Germany.
authors: Carsten
authors: C
authors: Weishaupt
authors: Dieter
authors: D
authors: Metze
authors: Thomas A
authors: TA
authors: Luger
authors: Sonja
authors: S
authors: Ständer
mesh_terms: D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003879:Dermatologic Agents / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D013492:Suppuration / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab